AIA: "Architecture firm billings remain stagnant" in November

Is the Future still Bright?

Assembly Biosciences announces Phase 1b data for ABI-4334

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

2026 US Economic Boost? Leading Indicators Point to "Data Center Construction Boom"

Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment

AIA: "Softness persists at architecture firms" in September

Promising Phase 1b Results for ABI-5366 Drive Buy Rating for Assembly Biosciences

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Route1 Inc. Enhances ABI Software with New Revenue and Parking Capabilities

AIA: "Softness persists at architecture firms" in August

OSL Group Completes Acquisition of Licensed Indonesian Exchange Koinsayang

UK Insurers Gain Insight into Carbon Footprint of Claims with New Verisk Calculator

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus